ADB-Binaca

ADB-BINACA
ADB-Binaca
ADB-BINACA structure.png
법적 상태
법적 상태
식별자
  • N-[(2S)-1-아미노-3, 3-디메틸-1-옥소부탄-2-일]-1-벤질-1H-인다졸-3-카르복사미드
CAS 번호
PubChem CID
켐스파이더
유니
화학 및 물리 데이터
공식C21H24N4O2
몰 질량364.449 g/g−1/g
3D 모델(JSmol)
  • O=C(NC(C(N)=O)C(C)(C)C1)C1=NN(CC2=CC=C2)C3=C1C=CC3
  • InChI=1S/C21H24N4O2/c1-21(2,3)18(22)26)23-20(27)17-15-11-7-8-12-16)25(24-17)13-14-9-5-6-10-14/12-18,12,13H,13H
  • 키: IUFIUAWRCUVUCQ-UHFFFAOYSA-N

ADB-BINACA는 일부 합성 대마초 제품의 [1]성분으로 발견된 대마초 디자이너 약입니다.원래 화이자(Phizer)에 의해 잠재적 진통제로 개발되었으며 결합 친화력(Ki)이 0.33nM, EC가50 14.[2]7nM인 CB 수용체의1 잠재적 작용제이다.

ADB-부티나카

ADB-부티나카
ADB-BUTINACA structure.png
법적 상태
법적 상태
식별자
  • N-[(2S)-1-아미노-3, 3-디메틸-1-옥소부탄-2-일]-1-부틸-1H-이다졸-3-카르복사미드
CAS 번호
PubChem CID
켐스파이더
화학 및 물리 데이터
공식C18H26N4O2
몰 질량330.432g/표준−1
3D 모델(JSmol)
  • O=C(N[C@H](C(N)=O)C(C)(C)C1=NN(CCCC)C2=C1C=CC=C2
  • InChI=1S/C18H26N4O2/c1-5-6-6-22-13-10-8-7-9-12(13)14(21)17(24)20-15(16)18(2,3)4/h7-10,15,5-6,112,
  • 키: GPWADX히자즈팩스오아흘로코사N

1-벤질 대신 1-부틸 치환을 가진 인다졸 고리 유사체는 ADB-BINACA라는 이름으로도 판매되었지만, 현재는 벤질 [3][4][5][6]화합물과의 혼동을 피하기 위해 ADB-BUTINACA로 더 일반적으로 언급되고 있다.EC가50 6.[7][8]36nM인 마찬가지로1 강력한 CB 작용제이다.

「 」를 참조해 주세요.

레퍼런스

  1. ^ Qian Z, Hua Z, Liu C, Jia W (2016). "Four types of cannabimimetic indazole and indole derivatives, ADB-BINACA, AB-FUBICA, ADB-FUBICA, and AB-BICA, identified as new psychoactive substances". Forensic Toxicology. 34: 133–143. doi:10.1007/s11419-015-0297-2. PMC 4705129. PMID 26793280.
  2. ^ WO 2009106982, "Indazole 파생상품"
  3. ^ Kavanagh P, Pechnikov A, Nikolaev I, Dowling G, Kolosova M, Grigoryev A (August 2021). "Detection of ADB-BUTINACA Metabolites in Human Urine, Blood, Kidney and Liver". Journal of Analytical Toxicology. doi:10.1093/jat/bkab088. PMID 34341821.
  4. ^ Sia CH, Wang Z, Goh EM, Tan YL, Fong CY, Moy HY, Chan EC (November 2021). "Urinary Metabolite Biomarkers for the Detection of Synthetic Cannabinoid ADB-BUTINACA Abuse". Clinical Chemistry. 67 (11): 1534–1544. doi:10.1093/clinchem/hvab134. PMID 34387654.
  5. ^ Kronstrand R, Norman C, Vikingsson S, Biemans A, Valencia Crespo B, Edwards D, et al. (November 2021). "The metabolism of the synthetic cannabinoids ADB-BUTINACA and ADB-4en-PINACA and their detection in forensic toxicology casework and infused papers seized in prisons". Drug Testing and Analysis. doi:10.1002/dta.3203. PMID 34811926. S2CID 244490343.
  6. ^ Wang, Yue; Pan, Yefei; Yang, Hongkun; Liu, Jinlei; Wurita, Amin; Hasegawa, Koutaro (2022). "Quantification of MDMB-4en-PINACA and ADB-BUTINACA in human hair by gas chromatography–tandem mass spectrometry". Forensic Toxicology. doi:10.1007/s11419-022-00615-z. ISSN 1860-8973.
  7. ^ Cannaert A, Sparkes E, Pike E, Luo JL, Fang A, Kevin RC, et al. (December 2020). "Synthesis and in Vitro Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA". ACS Chemical Neuroscience. 11 (24): 4434–4446. doi:10.1021/acschemneuro.0c00644. PMID 33253529. S2CID 227246346.
  8. ^ Pike E, Grafinger KE, Cannaert A, Ametovski A, Luo JL, Sparkes E, et al. (July 2021). "Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays: Part I-Synthesis, analytical characterization, and binding affinity for human CB1 receptors". Drug Testing and Analysis. 13 (7): 1383–1401. doi:10.1002/dta.3037. PMID 33787091.